Michael Barbella, Managing Editor05.25.21
Lantheus Holdings Inc. is strengthening its R&D team with the recent hiring of Bela Denes, M.D., and Iryna Teslenko, M.D. Both report directly to Lantheus Chief Medical Officer Istvan Molnar, M.D.
"At Lantheus, our ultimate goal is to use world-class science to help patients in need, and I am pleased to welcome two top-tier medical professionals to our Lantheus team to advance that mission,” said Molnar. “With the additions of Dr. Denes’ expertise in urology and Dr. Teslenko’s expertise in radiology, I am confident we are set up for success as we continue to develop our pipeline, particularly our prostate cancer radiopharmaceutical product candidates.”
Denes is a board-certified urologist who practiced for 25 years and subsequently has had a distinguished industry career. Prior to joining Lantheus, Denes was the global medical affairs lead at Amgen, responsible for overseeing the medical plans, launch preparation, and lifecycle management of three urology pipeline assets in development. Prior to joining Amgen, he served as vice president of Medical Affairs at Blue Earth Diagnostics until the company’s acquisition by Bracco Imaging in August 2019. Prior to Blue Earth Denes spent time at Genomic Health, Eli Lilly, Pfizer, Spectrum, and Abbott across medical affairs and clinical development. Additionally, Denes has presented and published numerous articles, abstracts, and posters at conferences both in the United States and abroad.
Teslenko is a physician, board-certified in radiology diagnostics, with more than 17 years of drug development and clinical research experience in solid tumor and hematological oncology. Before joining Lantheus, Teslenko worked as a physician program lead at GlaxoSmithKline (GSK), leading the cross-functional team responsible for development of GSK’s immuno-oncology assets. Prior to GSK, Teslenko worked in roles of increasing responsibility at PRA Health Sciences and PSI CRO AG, leading the hematology-oncology medical group and global medical monitoring and consulting group. Due to her strong expertise in medical imaging, she also served as an in-house medical imaging expert for PSI CRO AG and was responsible for the medical imaging aspects of the clinical trials run by the company, as well as for radiological trainings for the company’s employees and clinical investigators. Teslenko is an author of numerous publications in peer reviewed journals and book chapters on Good Clinical Practice and radiology diagnostics. She also earned a Master of Business Administration degree.
"At Lantheus, our ultimate goal is to use world-class science to help patients in need, and I am pleased to welcome two top-tier medical professionals to our Lantheus team to advance that mission,” said Molnar. “With the additions of Dr. Denes’ expertise in urology and Dr. Teslenko’s expertise in radiology, I am confident we are set up for success as we continue to develop our pipeline, particularly our prostate cancer radiopharmaceutical product candidates.”
Denes is a board-certified urologist who practiced for 25 years and subsequently has had a distinguished industry career. Prior to joining Lantheus, Denes was the global medical affairs lead at Amgen, responsible for overseeing the medical plans, launch preparation, and lifecycle management of three urology pipeline assets in development. Prior to joining Amgen, he served as vice president of Medical Affairs at Blue Earth Diagnostics until the company’s acquisition by Bracco Imaging in August 2019. Prior to Blue Earth Denes spent time at Genomic Health, Eli Lilly, Pfizer, Spectrum, and Abbott across medical affairs and clinical development. Additionally, Denes has presented and published numerous articles, abstracts, and posters at conferences both in the United States and abroad.
Teslenko is a physician, board-certified in radiology diagnostics, with more than 17 years of drug development and clinical research experience in solid tumor and hematological oncology. Before joining Lantheus, Teslenko worked as a physician program lead at GlaxoSmithKline (GSK), leading the cross-functional team responsible for development of GSK’s immuno-oncology assets. Prior to GSK, Teslenko worked in roles of increasing responsibility at PRA Health Sciences and PSI CRO AG, leading the hematology-oncology medical group and global medical monitoring and consulting group. Due to her strong expertise in medical imaging, she also served as an in-house medical imaging expert for PSI CRO AG and was responsible for the medical imaging aspects of the clinical trials run by the company, as well as for radiological trainings for the company’s employees and clinical investigators. Teslenko is an author of numerous publications in peer reviewed journals and book chapters on Good Clinical Practice and radiology diagnostics. She also earned a Master of Business Administration degree.